drugset / Trial / NCT02894138

Optimal Coronary Flow After PCI for Myocardial Infarction - a Pilot Study

NCT02894138

Phase 3 Unknown 80 enrolled Vastra Gotaland Region
RandomizedParallel-groupDouble-blindTreatment

Summary

In this study the investigators test the hypothesis that alteplase given intra coronary after PCI reduce infarct size in patients with ST-elevation myocardial infarction(STEMI) and impaired microvascular function defined as a value of index of microvascular resistance (IMR) \>30.

Timeline

Start
2016-09
Primary completion
2021-12
Completion
2022-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Alteplase Protein / enzyme biologic 20 mg Other